All the news Showing 7 of 27 articles from: New and experimental treatments for hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones Liz Highleyman / 15 November 2016 Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss, according to a report this ... New Tenofovir Formulation Provides Safer Hepatitis B Treatment Medscape (free registration required) / 03 October 2016 Core inhibitor NVR 3-778 plus pegylated interferon inhibits hepatitis B activity Liz Highleyman / 05 May 2016 NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA and hepatitis B 'e' antigen (HBeAg), showing greater activity when ... REP 2139 shows promise for people with hepatitis B and hepatitis delta co-infection Liz Highleyman / 16 November 2015 The nucleic acid-based polymer REP 2139, used first as monotherapy then combined with pegylated interferon, reduced hepatitis B surface antigen (HBsAg) levels, lowered hepatitis delta viral load and increased anti-HBs antibody titres, according ... Johnson and Johnson acquires Novira to expand HBV pipeline Healio Hepatology / 11 November 2015 Novel Therapeutic Approches to Cure Chronic HBV Infection EASL / 26 April 2013 Arrowhead data demonstrates RNAi candidate ARC-520 silences hepatitis B virus Arrowhead Research Corp press release / 27 February 2013 ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive